representative sample of alcoholics emphasizes a broader picture of transcriptome differences within PFC that are related to disease. Transcriptome signatures defined by GMs in Group1 for lifetime alcohol consumption contain targets for several pharmaceutical agents that have the potential to curb alcohol intake, including the prescription drug gabapentin (P = 4.91e-07). A randomized clinical trial for alcohol dependence has previously shown the effectiveness of gabapentin on heavy drinking and prolonging abstinence 75. Combining clinical and transcriptome results demonstrates a practical utility of this and related studies to determine potential pharmacotherapies for alcohol abuse. Polymorphisms conferring the risk of developing alcohol dependence may influence network substructures related to alcohol drinking behavior and dictate logical treatment options. The results of our integrative study emphasize the power of high-throughput sequencing of human postmortem brain tissue as an intermediate resource for uncovering novel molecular mechanisms in human disease and as a means of informing personalized medicine for the treatment of alcohol use disorders.
